138 related articles for article (PubMed ID: 24344948)
21. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
22. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation.
Shuker N; Shuker L; van Rosmalen J; Roodnat JI; Borra LC; Weimar W; Hesselink DA; van Gelder T
Transpl Int; 2016 Nov; 29(11):1158-1167. PubMed ID: 27188932
[TBL] [Abstract][Full Text] [Related]
23. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.
Shrestha BM
Exp Clin Transplant; 2017 Feb; 15(1):1-9. PubMed ID: 27938316
[TBL] [Abstract][Full Text] [Related]
24. Tacrolimus: a further update of its use in the management of organ transplantation.
Scott LJ; McKeage K; Keam SJ; Plosker GL
Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
[TBL] [Abstract][Full Text] [Related]
25. Pediatric renal transplantation under tacrolimus-based immunosuppression.
Shapiro R; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Gilboa N; Gritsch HA; Irish W; McCauley J; Fung JJ; Hakala TR; Simmons RL; Starzl TE
Transplantation; 1999 Jan; 67(2):299-303. PubMed ID: 10075598
[TBL] [Abstract][Full Text] [Related]
26. Clinically significant drug-drug interaction between tacrolimus and phenobarbital: the price we pay.
Siddiqi N; Marfo K
J Pharm Pract; 2010 Dec; 23(6):585-9. PubMed ID: 21507867
[TBL] [Abstract][Full Text] [Related]
27. Tacrolimus based immunosuppression.
First MR
J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
29. Reversible encephalopathy associated with tacrolimus in pediatric renal transplants.
Parvex P; Pinsk M; Bell LE; O'Gorman AM; Patenaude YG; Gupta IR
Pediatr Nephrol; 2001 Jul; 16(7):537-42. PubMed ID: 11465799
[TBL] [Abstract][Full Text] [Related]
30. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
[TBL] [Abstract][Full Text] [Related]
31. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
32. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Jardine AG
Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
[TBL] [Abstract][Full Text] [Related]
33. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling.
Diémé B; Halimi JM; Emond P; Büchler M; Nadal-Desbarat L; Blasco H; Le Guellec C
Transplantation; 2014 Jul; 98(2):195-201. PubMed ID: 24598938
[TBL] [Abstract][Full Text] [Related]
34. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
[TBL] [Abstract][Full Text] [Related]
35. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Chakrabarti P; Wong HY; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Hakala TR; Fung JJ; Simmons RL; Starzl TE; Shapiro R
Transplantation; 2000 Sep; 70(5):760-4. PubMed ID: 11003353
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients.
Sung J; Barry JM; Jenkins R; Rozansky D; Iragorri S; Conlin M; Al-Uzri A
Pediatr Transplant; 2013 Dec; 17(8):718-25. PubMed ID: 24164824
[TBL] [Abstract][Full Text] [Related]
37. Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Baran DA; Galin ID; Gass AL
Am J Cardiovasc Drugs; 2004; 4(1):21-9. PubMed ID: 14967063
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
40. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
